Certara is dedicated to improving human health by offering a broad spectrum of software products and services, with special focus on supporting translational approaches to drug development.
Jim Hopkins, Chief Executive Officer
Patrick Flanagan, Chief Operating Officer and SVP, Consulting Services
John D. Yingling, Chief Financial Officer
Daniel L. Weiner, Ph.D., Senior Vice President and General Manager, Software
Gregory B. Smith, Chief Technology Officer
Richard D. Cramer III, Ph.D., Chief Scientific Officer
James Hayden, Senior Vice President, Global Sales and Marketing
Mark Hovde, Senior Vice President, Business Development
JF Marier, Ph.D., FCP, Vice President and Lead Scientist, Consulting Services, North America
Rene Bruno, Ph.D., Managing Director, Consulting Services, Europe
Mr. Hopkins joined Certara via Tripos in March of 2007. During the ten years prior to joining Tripos, Mr. Hopkins has been an executive officer or served on the boards of more than a dozen public and private companies. Most recently he was Chairman and CEO of Micrografx, Inc., a Texas-based Nasdaq-listed graphics software company that was sold to Corel Corporation. He became acquainted with Vector Capital while on the Board of Directors of Corel as a result of Vector’s purchase of Corel. He has taken companies through the IPO and Secondary public offering processes, and has conducted strategic acquisitions and sales of both public and private companies.
Mr. Flanagan joined Certara via Tripos in 2007, and currently leads both Pharsight and Tripos in his role as COO. He came to Tripos with a 15-year career in strategic sales and business development for leading companies in the healthcare, software, and consulting fields including Baxter International, Allegiance Healthcare, A.T. Kearney and Oracle. Mr. Flanagan holds a BS in Business from Penn State University and an MBA with a concentration in Finance and Marketing from the Kellogg Graduate School of Management at Northwestern University.
Mr. Yingling joined Certara via Tripos International in March 2007. He received his B.S. degree in Accounting from the University of Missouri, St. Louis, in 1979 and holds certificates as a Certified Public Accountant and a Certified Cash Manager. Mr. Yingling worked for Storz Instrument Company, a micro-surgical instrument manufacturer, in a series of accounting positions from 1979 to 1983 and for Clayton Brokerage Company from 1983 to 1985. This was followed by several accounting, tax and treasury positions at Venture Stores, Inc. from 1985 to 1995. Mr. Yingling joined Tripos, Inc. in May 1995 as U.S. Controller and was promoted to Corporate Controller & Treasurer, then to Vice President, Chief Accounting Officer and ultimately to Chief Financial Officer in October, 2006.
Dr. Weiner has extensive drug development experience and has served as an expert consultant to the U.S. Food and Drug Administration (FDA) on pharmacokinetic modeling and bioequivalence assessment. Prior to his previous tenure with Pharsight as a Senior Vice President, Dr. Weiner held several management positions including Head, Biostatistics, Merrell Dow Pharmaceuticals; Vice President, Statistical Consultants, Inc.; Vice President, Syntex Development Research; Senior Vice President and Principal Scientist, Quintiles, and most recently, Senior Vice President and Global Head of Clinical Development at IVAX Research. Dr. Weiner graduated from the University of Kentucky with a doctoral degree in Mathematical Statistics, with emphasis on compartmental modeling, as well as an M.S. in Statistics, and a B.S. in Mathematics.
He is the co-author of Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications. Dr. Weiner is a past Adjunct Associate Professor with the Colleges of Pharmacy and Environmental Health at the University of Cincinnati; a past President of the Greater Cincinnati Chapter of the American Statistical Association; a past Vice-Chair of the Biostatistics Subsection of PMA; and a past member of the Editorial Advisory Board for the Journal of Pharmaceutical Sciences.
Mr. Smith joined Certara via Tripos in March 2007. Previously, while a graduate student at Washington University, in St. Louis, Missouri, Mr. Smith's research focused on the initial development of SYBYL, the program that would transition commercially into Tripos' premiere computational chemistry platform. In 1984, after finishing his studies with a B.S. and M.S. in computer science, he joined AT&T Bell Laboratories as a researcher, concentrating his efforts in formal language design and intelligent workstation development. In 1986, Mr. Smith joined Tripos, Inc., where he played a key role in designing and developing numerous commercial products for the company, including UNITY, SPL, the Molecular Spreadsheet, and the Tripos Electronic Notebook. In his 20+ years at Tripos, Inc. Mr. Smith held Director of Cheminformatics and Senior Fellow positions and accepted many leadership roles, including Vice President of Development and Chief Technology Officer.
Dr. Cramer joined Tripos International in March 2007, and served as the vice president for science at Tripos, Inc., for the past 24 years. Dr. Cramer is best known for the invention of CoMFA®, the first and most widely used 3D-QSAR technique. He is also the founder and former chief technical officer of STATS, Inc., the leading provider of sports statistical information. The company was eventually purchased by Fox Sports. Dr. Cramer received his PhD in Physical Organic Chemistry from MIT.
Mr. Hayden has 15 years of experience in sales, marketing and management within the life sciences industry. Before joining Certara’s Pharsight division, Mr. Hayden was the National Director of Sales for Accelrys, Inc., a leading provider of software for computation, simulation, and the management and mining of scientific data used by biologists, chemists and materials scientists. While at Accelrys, he led a sales team responsible for major account sales of the company’s software solutions in the Americas region. In this role, he successfully reestablished the company’s presence in a failing geographical region and also developed a variety of sales infrastructure tools that allowed the company to gauge the progress of its sales team. Prior to this, he was a leading sales representative at Bio-Rad Laboratories, a developer of innovative tools and services for the clinical diagnostics and life sciences research markets. Mr. Hayden began his career as an electrical engineer at Raytheon and holds an MBA from Rutgers University and a B.S. in Electrical Engineering from Boston University.
Mr. Hovde has more than 15 years of experience in marketing and business development for pharmaceutical software, data, and services companies. Prior to joining Certara via Pharsight, Mr. Hovde was the President and founder of Hovde Associates, LLC, and a management consulting firm specializing in counsel on pharmaceutical development. Prior to this, he was the Vice President, Sales and Business Development at Fast Track Systems, Inc., a developer of software focused on improving the protocol quality and the speed of the clinical trial process. While at Fast Track, Mr. Hovde was responsible for the formation and management of the company’s sales and marketing organizations and successfully created a unique consulting services program, which was offered to the company’s major accounts. Mr. Hovde was also the co-founder of DataEdge, LLC, a developer of novel informatics that help reduce the time and cost of clinical trials. At DataEdge pioneered the PICAS and CROCAS databases, leading clinical cost benchmarking tools, which improved trial cost control. Today PICAS and CROCAS are used to benchmark over 50% of worldwide investigator, CRO, and central lab spending. Mr. Hovde has authored several publications and presentations and holds a Bachelor of Science degree in Finance from the Wharton School of the University of Pennsylvania, where he was also named a Benjamin Franklin Scholar, and an MBA from Harvard Business School.
Dr. Marier has directed PK/PD analyses, reporting, and modeling and simulation projects for hundreds of studies in early and late clinical research. His drug development experience spans noncompartmental and population PK/PD modeling and simulation across all phases of development and in specific populations (pediatric/geriatric, renal/liver impaired). His expertise includes scientific and regulatory consultation on drug development programs for small and large molecules, particularly in the therapeutics areas of oncology, inflammation, immunosuppressants, cardiovascular, infection and metabolic diseases. Dr. Marier has authored or co-authored more than 100 abstracts/manuscripts and book chapters in the field of PK/PD, and has leveraged modeling and simulation to build and optimize drug development programs for dozens of industry sponsors. Dr. Marier earned his Ph.D. in Pharmaceutical Sciences from the University of Montreal, Faculty of Pharmacy and is a fellow of the American College of Clinical Pharmacology.
Prior to joining Certara’s Pharsight division, Dr. Bruno spent the last three years at Genentech, Inc. in South San Francisco, Calif., where he was most recently senior scientist and head of the pharmacometry unit. Before Genentech, Dr. Bruno held various scientific research positions, including research advisor, over the course of 13 years at Rhone-Poulenc Rorer in Antony, France and Collegeville, Pa. Prior to Rhone-Polenc Rorer, Dr. Bruno was a pharmacokineticist at Syntex Research in France. To date, he has authored or co-authored more than 130 manuscripts and scientific communications in the field of drug development. Dr. Bruno has undertaken extensive work in the areas of modeling and simulation and has been an industry leader in supporting this methodology in the drug development process across several global projects. Dr. Bruno holds a Ph.D. in pharmacology from the University of Aix-Marseille, department of Pharmacokinetics and Toxicokinetics in School of Pharmacy. In addition, he holds a “Habilitation a des Recherches” from University of Aix-Marseille, the highest academic degree in France. Dr. Bruno held a “Maitre-Assistant” (Assistant Professor) position in the department of Pharmacokinetics and Toxicokinetics, School of Pharmacy, Marseilles before moving to the Pharmaceutical Industry.
From Discovery through Development
Certara's goal is to provide solutions in predictive science, communication and informatics that facilitate the elimination of barriers to bi-directional sharing of information.
Search Our Archives
